Patent US4601894A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4601894A Expired / Lapsed US ⏱️ 0.0 years remaining

Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate

Assignee: Merck Sharp & Dohme LLC
•
Filing: 1985-03-29
•
Granted: 1986-07-22
•
Expires: 2005-03-29
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The invention relates to a controlled release dosage form comprising three actives: acetaminophen, psueudoephedrine sulfate and dexbrompheniramine maleate.

Inventors

  • 👤 Gayda Hanna
  • 👤 Winston A. Vadino

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-31 10:06
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/20; A61K9/2004; A61K9/2022; A61K9/205; A61K9/2054; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/44; A61K9/2009

Claims Analysis

Total Claims: 15
Claim 1
Independent Claim 67 words
An oral dosage form comprising an analgesic-effective amount of acetaminophen, an amount of pseudoephedrine or a pharmaceutically acceptable salt thereof effective in reducing nasal congestion, and an antihistaminic-effective amount of dexbrompheniramine or a pharmaceutically acceptable salt thereof in a uniform matrix comprising a controlled release carrier comprised of a polymer selected from hydroxypropyl methylcellulose ethers or a combination of polymers selected from hydroxypropyl methylcellulose ethers and ethylcellulose.
Claim 2
Dependent Claim 67 words
An oral dosage form comprising an analgesic-effective amount of acetaminophen, an amount of pseudoephedrine or a pharmaceutically acceptable salt thereof effective in reducing nasal congestion, and an antihistaminic-effective amount of dexbrompheniramine or a pharmaceutically acceptable salt thereof in a uniform matrix comprising a controlled release carrier comprised of a polymer selected from hydroxypropyl methylcellulose ethers or a combination of polymers selected from hydroxypropyl methylcellulose ethers and ethylcellulose.
Claim 3
Dependent Claim 28 words
A dosage form of claim 1 comprising 400 to 750 mg of acetaminophen, 15 to 75 mg of pseudoephedrine sulfate, and 1 to 5 mg of dexbrompheniramine maleate.
Claim 4
Dependent Claim 19 words
A dosage form of claim 2 comprising 500 mg acetaminophen, 60 mg pseudoephedrine sulfate and 3 mg dexbrompheniramine maleate.
Claim 5
Dependent Claim 61 words
A dosage form of claim 1 wherein the carrier comprises a polymer, wherein the polymer is comprised of 100-60% hydroxypropyl methylcellulose ethers and 0-40% ethylcellulose, one or more lubricants selected from stearic acid, magnesium stearate, calcium stearate, waxes, polyethylene glycol and magnesium lauryl sulfate, and one or more fillers selected from the group consisting of dibasic calcium phosphate dihydrate and lactose.
Claim 6
Dependent Claim 44 words
A dosage form of claim 4 wherein the total polymer weight represents 1-8% of the total dosage form weight, the total binder weight represents 11-13% of the total dosage form weight, and the total lubricant weight represents 1-3% of the total dosage form weight.
Claim 7
Dependent Claim 13 words
A dosage form of claim 5 wherein the polymer is 100% hydroxypropyl methylcellulose.
Claim 8
Dependent Claim 15 words
A dosage form of claim 5 wherein the polymer is 100% hydroxypropyl methylcellulose USP 2208.
Claim 9
Dependent Claim 14 words
A dosage form of claim 5 wherein the filler is dibasic calcium phosphate dihydrate.
Claim 10
Dependent Claim 15 words
A dosage form of claim 5 wherein the lubricants are stearic acid and magnesium stearate.
Claim 11
Dependent Claim 26 words
A dosage form of claim 5 comprising 1-8% hydroxypropyl methylcellulose, 10-13% dibasic calcium phosphate dihydrate and 1-3% of a combination of stearic acid and magnesium stearate.
Claim 12
Dependent Claim 12 words
A dosage form of claim 10 comprising 1-8% hydroxypropyl methylcellulose USP 2208.
Claim 13
Dependent Claim 25 words
A dosage form of claim 11 comprising 400 to 750 mg acetaminophen, 15 to 75 mg pseudoephedrine sulfate and 1 to 5 mg dexbrompheniramine maleate.
Claim 14
Dependent Claim 40 words
A dosage form comprising 500 mg acetaminophen, 60 mg pseudoephedrine sulfate, 3 mg dexbrompheniramine maleate, 48 mg hydroxypropyl methylcellulose USP 2208, 95 mg dibasic calcium phosphate dihydrate, 10 mg stearic acid and 4 mg magnesium stearate in a uniform matrix.
Claim 15
Dependent Claim 40 words
A dosage form comprising 500 mg acetaminophen, 60 mg pseudoephedrine sulfate, 3 mg dexbrompheniramine maleate, 48 mg hydroxypropyl methylcellulose USP 2208, 95 mg dibasic calcium phosphate dihydrate, 10 mg stearic acid and 4 mg magnesium stearate in a uniform matrix.

References Cited (Backward Citations)

US3065143A Cited
US4226849A Cited
US4259314A Cited
US4369172A Cited
US4389393A Cited
US4389393B1 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1989-07-21 1990-01-20 1990-07-22 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1993-07-21 1994-01-20 1994-07-22 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1997-07-21 1998-01-20 1998-07-22 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag